UroGen Pharma General Counsel Jason Drew Smith exercised Options for 3,334 shares and later sold 1,519 shares at $42.54 each. His resulting holding was 53,141 shares after the sale, while the option exercise left him with no derivative securities. The transactions alter his direct Equity exposure.
Key Highlights
- Smith Jason Drew held 54,660 shares after exercising options.
- The option exercise represented 100.0% of his prior derivative securities holding.
- The later sale represented about 2.8% of his prior shares holding.
UroGen Pharma Ltd. (NASDAQ: URGN) General Counsel Jason Drew Smith sold 1,519 shares at $42.54 per share on Sep. 8. His share ownership afterward stood at 53,141 shares.
Option Exercise and Resulting Holdings
Smith exercised options for 3,334 shares on Sep. 7, leaving him with 54,660 shares after the transaction. The exercise represented about 6.1% of his resulting shares holding. The same Sep. 7 transaction covered 3,334 derivative securities. Smith then owned zero derivative securities, representing about 100.0% of his prior derivative securities holding.
FAQs
Q: What did UroGen Pharma General Counsel Jason Drew Smith do?
A: Jason Drew Smith exercised options for 3,334 UroGen Pharma shares on Sep. 7. He sold 1,519 shares at $42.54 per share on Sep. 8.
Q: How many UroGen Pharma shares did Jason Drew Smith own afterward?
A: Smith owned 53,141 UroGen Pharma shares after the sale. He held 54,660 shares after exercising the options before that transaction.
Q: What happened to Jason Drew Smith’s derivative securities?
A: Smith exercised options for 3,334 derivative securities. His resulting derivative securities holding was zero, representing 100.0% of his prior holding.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.